Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.
Official title: A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies
Key Details
Gender
All
Age Range
18 Years - 66 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2022-02-16
Completion Date
2028-08
Last Updated
2025-11-20
Healthy Volunteers
No
Conditions
Interventions
Human T Lymphoid Progenitor (HTLP) injection
The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
Locations (5)
Hôpital Saint Louis
Paris, France
Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux
Pessac, France
IUCT Oncopole Toulouse
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Hematology department / Necker Children's Hospital
Paris, Île-de-France Region, France